Are GLP-1 Medications Different for Diabetes vs Weight Loss?
Last updated: January 2026
Quick Answer
The same active ingredients treat both conditions at similar doses. Brand names differ: Ozempic/Wegovy (semaglutide), Mounjaro/Zepbound (tirzepatide).
Are GLP-1 Medications Different for Diabetes vs Weight Loss
The same active ingredients treat both conditions at similar doses. Brand names differ: Ozempic/Wegovy (semaglutide), Mounjaro/Zepbound (tirzepatide).
GLP-1 medication eligibility is determined by your healthcare provider based on your BMI, health conditions, and medical history. The FDA guidelines provide the framework, but individual providers may have additional criteria or be willing to evaluate borderline cases.
Standard Eligibility Criteria
- BMI of 30 or higher (obese)
- BMI of 27 or higher with at least one weight-related comorbidity
- Common qualifying comorbidities: type 2 diabetes, hypertension, dyslipidemia, sleep apnea, PCOS
- No contraindications such as medullary thyroid carcinoma history or MEN 2 syndrome
The Evaluation Process
Your telehealth provider will review your health history, current medications, and weight management goals. Most online assessments take under 10 minutes. If you qualify, a licensed prescriber will create a treatment plan tailored to your specific needs and health profile.
If you are unsure whether you qualify, many telehealth providers offer free initial assessments with no obligation. This allows you to find out if GLP-1 treatment is appropriate for you without any financial risk.
Related Questions
Semaglutide vs Tirzepatide: Which Is Better?
Tirzepatide shows higher average weight loss (20-22% vs 15%) by targeting two receptors. Semaglutide has more long-term safety data and lower starting cost.
Who Qualifies for GLP-1 Weight Loss Medications?
Adults with BMI 30+ or BMI 27+ with a weight-related condition (diabetes, hypertension, sleep apnea, etc.) typically qualify for GLP-1 medications.